Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) (SERENITY)

16 de noviembre de 2026 actualizado por: argenx

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants With Sjogren's Disease-Associated Sensorimotor or Sensory Polyneuropathy

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

Descripción general del estudio

Descripción detallada

The study will be conducted in adult participants with moderate-to-severe SjD and SjD-associated sensorimotor polyneuropathy (SMPN) or sensory polyneuropathy (SPN). The study consists of two parts. Part A is a randomized, double-blinded, placebo-controlled, parallel-group treatment period designed to evaluate the efficacy and safety of efgartigimod hyaluronidase (PH20) subcutaneously (SC) or placebo. Following the completion of part A, the double-blinded treatment period (DBTP) participants will enter part B, an open-label treatment period (OLTP) to assess long-term safety, tolerability, and durability of response of efgartigimod PH20 SC.

The overall study duration will be up to 108 weeks for each participant.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

75

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Sarasota, Florida, Estados Unidos, 34239
        • Reclutamiento
        • Sarasota Arthritis Research Center
        • Contacto:
        • Investigador principal:
          • Jaishree Manohar, Dr.
      • Tampa, Florida, Estados Unidos, 33614
        • Reclutamiento
        • Vantage Clinical Trials Tampa
        • Contacto:
        • Investigador principal:
          • Edgard Janer, Dr.
    • Michigan
      • Sterling Heights, Michigan, Estados Unidos, 48313
        • Reclutamiento
        • Revive Research Institute Inc
        • Contacto:
        • Investigador principal:
          • Syed Husain, Dr.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF
  • Meets the following SjD criteria: Fulfilled American College of Rheumatology and the European Alliance of Associations for Rheumatology classification 2016 SjD criteria before screening; Moderate-to-severe disease defined as a ESSDAI ≥ 5 or clinESSDAI ≥ 6 with PNS domain score of ≥ 5 (ie, a score of at least low activity) at screening; Anti-Ro/SS-A positive at a central laboratory at screening
  • Meets the following SjD-associated polyneuropathy criteria: Diagnosis of SjD-associated SMPN, SPN or sensory ganglionopathy, with neuropathy duration ≤ 5 years at screening and signs of active neuropathic disease development within the last 12 months; patients with co-existing SjD-associated small fiber neuropathy are eligible; No alternative diagnosis of neuropathy etiology; Total mTCNS ≥ 6 at screening; mTCNS sensory test score <level 3 at screening (does not apply to sensory ganglionopathy cohort where any severity is acceptable)

Exclusion Criteria:

  • Besides the indication under study, known medical conditions that would interfere with an accurate assessment of clinical symptoms of SjD-associated SMPN or SPN or gangliopathy, confound the study results, or puts the participant at undue risk.
  • Associated (also known as secondary) SjD, defined as overlap with another autoimmune rheumatic or systemic inflammatory condition (eg, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or idiopathic inflammatory myopathy).
  • Active fibromyalgia which is not adequately controlled in the judgment of the investigator, or participant is receiving fibromyalgia treatment that has not been stable treatment for at least 12 weeks before screening.
  • An alternative etiology for SMPN/SPN/sensory ganglionopathy or insufficient evidence of the diagnosis.
  • Any severe SjD manifestation or other health condition not adequately controlled at screening or baseline that may put the participant at undue risk based on the investigator's opinion.
  • Comorbidities (eg, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic (oral, IV, or IM) glucocorticoids within the previous 12 months.
  • History of malignancy unless considered cured by adequate treatment with no evidence of recurrence for ≥ 3 years; before first IMP administration.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Double-blinded treatment period (DBTP): Efgartigimod PH20 SC

Participants receiving efgartigimod PH20 SC during the double-blinded treatment period

subcutaneous efgartigimod PH20 SC given by prefilled syringe

Comparador de placebos: Double-blinded treatment period (DBTP): Placebo PH20 SC

Participants receiving placebo PH20 SC during the double-blinded treatment period

subcutaneous placebo PH20 SC given by prefilled syringe

Experimental: Open-label treatment period (OLTP)

Participants receiving efgartigimod PH20 SC during the open-label treatment period

subcutaneous efgartigimod PH20 SC given by prefilled syringe

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part A
Periodo de tiempo: Up to 48 weeks

The mTCNS (modified Toronto Clinical Neuropathy Score) is a clinician-reported outcome measure derived from the original TCNS to improve sensitivity to early and mild neuropathy and to enhance feasibility and consistency inclinical research settings. The total mTCNS score is calculated as the sum of the symptom and sensory subscores, yielding a total possible score range of 0 to 33, with higher scores indicating greater neuropathy severity.

Up to 48 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score over time
Periodo de tiempo: up to 96 weeks

The mTCNS (modified Toronto Clinical Neuropathy Score) is a clinician-reported outcome measure derived from the original TCNS to improve sensitivity to early and mild neuropathy and to enhance feasibility and consistency inclinical research settings. The total mTCNS score is calculated as the sum of the symptom and sensory subscores, yielding a total possible score range of 0 to 33, with higher scores indicating greater neuropathy severity.

up to 96 weeks
Change from baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The Norfolk QoL-DN is a patient-reported outcome (PRO) instrument designed to assess neuropathy symptom severity and the impact of peripheral neuropathy on participants' ability to complete activities of daily living (ADLs). The Norfolk QoL-DN consists of 35 items that assess the presence and severity of sensory symptoms (eg, numbness, tingling, pain), motor and balance difficulties, and the extent to which neuropathy interferes with daily activities, sleep, work, and social functioning.

up to 96 weeks
Change from baseline in clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) score at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) was designed to measure systemic disease activity in patients with SjD. The ESSDAI consists of 12 domains, and the final score falls between 0 (no disease activity) and, theoretically, 123 (maximum disease activity). Clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) includes all ESSDAI domains except the biological domain. The clinical domains in clinESSDAI have different weights than in ESSDAI.

up to 96 weeks
Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The ESSDAI was designed to measure systemic disease activity in patients with SjD. The ESSDAI consists of 12 domains, and the final score falls between 0 (no disease activity) and, theoretically, 123 (maximum disease activity).

up to 96 weeks
Proportion of participants with low disease activity (clinESSDAI < 5) at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The ESSDAI was designed to measure systemic disease activity in patients with SjD. The ESSDAI consists of 12 domains, and the final score falls between 0 (no disease activity) and, theoretically, 123 (maximum disease activity). clinESSDAI includes all ESSDAI domains except the biological domain. The clinical domains in clinESSDAI have different weights than in ESSDAI.

up to 96 weeks
Incidence of AEs
Periodo de tiempo: Up to 104 weeks

Incidents are identified by measuring clinically significant changes in vital signs, physical examination, ECG, and clinical laboratory safety evaluations.

Up to 104 weeks
Change from baseline in Neuropathic Pain Questionnaire (NPQ) at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The NPQ is a self-administered PRO used to characterize the qualitative features of neuropathic pain. Responses are combined using a predefined scoring algorithm to generate a summary score reflecting the presence and prominence of neuropathic pain features.

up to 96 weeks
Change from baseline in the Difficulty Thinking Numerical Rating Scale (NRS) at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The Difficulty Thinking Numerical Rating Scale (NRS) is a SjD-specific symptom severity diary that has been developed specifically for the purpose of assessing disease severity in participants with SjD. An 11-point Likert response scale is used from 0 (no difficulty thinking) to 10 (worst possible difficulty thinking).

up to 96 weeks
Change from baseline in Patient Global Impression of Severity (PGIS) scores at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The PGIS of neuropathy severity is a single-item questionnaire that asks participants to provide a self-assessment of their overall neuropathy severity, using a 5-point scale.

up to 96 weeks
Change from baseline in Patient Global Impression of Change (PGIC) scores at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The PGIC of neuropathy severity is a single-item questionnaire that asks the participant to provide a self-assessment of change in their neuropathy severity using a 7-point scale compared to just before the participant started taking the IMP.

up to 96 weeks
Change from baseline in Clinical Global Impression of Severity (CGIS) scores at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The CGI of SjD-associated SMPN or SPN severity is a 1-item questionnaire that asks the clinician to provide an assessment of their patients' neuropathy severity on a 5-point scale at the time of the visit.

up to 96 weeks
Change from baseline in Clinical Global Impression of Change (CGIC) scores at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The CGIC of SjD-associated SMPN or SPN severity is a 1-item questionnaire that asks the clinician to provide the overall change in their patients' neuropathy severity on a 7-point scale, compared to just before participant started taking the IMP.

up to 96 weeks
Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scores at the end of part A and over time
Periodo de tiempo: up to 96 weeks

The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale assesses fatigue and its impact on patient's everyday lives, with a 7-day recall. It comprises 13 items, with responses of each of the items using a 5-point Likert scale ranging from 1 (Not at all) to 5 (Very much).

up to 96 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de octubre de 2026

Finalización primaria (Estimado)

28 de julio de 2028

Finalización del estudio (Estimado)

28 de julio de 2029

Fechas de registro del estudio

Enviado por primera vez

29 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

7 de agosto de 2026

Publicado por primera vez (Actual)

12 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ARGX-113-15-SJD-2003
  • 2026-526218-10-00 (Ctis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir